by Johns Hopkins University Bloomberg School of Public Health Strains of a common subtype of influenza virus, H3N2, have almost universally acquired a mutation that effectively blocks antibodies from binding to a key viral protein, according to a study from researchers at Johns Hopkins Bloomberg School of Public Health. The results have implications for flu...
by American College of Physicians A single dose of adjuvanted FLU-v, a synthetic universal flu vaccine, may provide long-lasting protection across a broad spectrum of influenza viruses. Findings from a randomized, double-blind, placebo-controlled trial are published in Annals of Internal Medicine. Currently, the best available prophylactic treatment against influenza is annual vaccination with inactivated or...
